Home › Head and Neck Squamous Cell Carcinoma › Rhode Island
Head and Neck Squamous Cell Carcinoma clinical trials in Rhode Island
7 studies for Head and Neck Squamous Cell Carcinoma are looking for participants at sites in Rhode Island.
Cities in Rhode Island
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Site #0132, Providence
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06788990Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- Smilow Cancer Hospital Care Center - Westerly, Westerly
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT02734537Head and Neck Cancer Study Project in the Geriatric Population
- Rhode Island and The Miriam Hospitals, Providence
RecruitingPhase 3
Ages 65 and older · All sexes · Updated Aug 20, 2026 · NCT06998069Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Lifespan Cancer Institute at Rhode Island Hospital /ID# 225705, Providence
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT04777994A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Women & Infants Hospital, Providence
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT05902988A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
- Rhode Island Hospital, Providence
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 15, 2025 · NCT06699212Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Rhode Island Hospital, Providence
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 15, 2025 · NCT04429542From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.